Showing results (221-230 of 248) with videos related to
Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2019
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline UpdateKala Visvanathan, Carol J Fabian, Elissa Bantug, et al.Investigational New Drugs|October 13, 2018
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-βClinton Yam, Rashmi K Murthy, Gaiane M Rauch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Ductal carcinoma in situ: state of the science and roadmap to advance the fieldHenry M Kuerer, Constance T Albarracin, Wei T Yang, et al.Breast Cancer Research and Treatment|December 6, 2013
Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancerYanhong Liu, Renke Zhou, Lars O Baumbusch, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 26, 2017
A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectivesM A Nguyen, T Flanagan, M Brewster, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer SubtypeW Fraser Symmans, Caimiao Wei, Rebekah Gould, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid TumorsAlexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertaseG Beck, G Bottomley, D Bradshaw, et al.The Journal of Physiology|November 4, 2025
Exercise and hypoxia independently stimulate platelet liberation of brain-derived neurotrophic factor and platelet factor 4K N Thomas, H G Caldwell, D B Macleod, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic VariantJennifer K Litton, Marion E Scoggins, Kenneth R Hess, et al.Pageof 25